Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its clinical development programs. “The second quarter focused largely on the execution of our development programs with itolizumab and our plans to advance the clinical development